STOCK TITAN
  1. Home
  2. Sec-filings
  3. VIVS
  4. [ARS] VivoSim Labs, INC. SEC Filing

[ARS] VivoSim Labs, INC. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
ARS

Rhea-AI Filing Summary

Analyzing...
ARS - VivoSim Labs, INC.

ARS Filing - VivoSim Labs, INC.

This filing is available as a PDF document.

Filing Type: ARS

Company: VivoSim Labs, INC. (VIVS)

Acceptance Date: 2025-11-06T16:52:12.000Z

View PDF Document

Source: View Original Filing on SEC EDGAR

VivoSim Labs Inc

NASDAQ:VIVS

View VIVS Stock Overview →

VIVS Rankings

#6717 Ranked by Market Cap
N/A Ranked by Dividends

VIVS Latest News

Mar 3, 2026
VivoSim Appoints Arumugham (Ragoo) Raghunathan as Vice President of Global Sales
Feb 11, 2026
VivoSim to Debut Antibody Drug Conjugate Data, representing a major new market for NAMkind models, at Society of Toxicology Meeting in San Diego
Jan 29, 2026
VivoSim Expands Asia-Pacific Access to NAMKind™ Human-Based Toxicology Services Through New Distributor Agreement in Korea and China
Jan 6, 2026
VivoSim Labs Appoints Amar Sethi, M.D., Ph.D. as Chief Scientific Officer
Aug 14, 2025
VivoSim Labs Appoints Tony Lialin as Chief Commercial Officer

VIVS Latest SEC Filings

Feb 11, 2026
[10-Q] VivoSim Labs, INC. Quarterly Earnings Report
Jan 29, 2026
[Form 4] VivoSim Labs, INC. Insider Trading Activity
Jan 29, 2026
[Form 4] VivoSim Labs, INC. Insider Trading Activity
Jan 29, 2026
[Form 4] VivoSim Labs, INC. Insider Trading Activity
Jan 29, 2026
[Form 4] VivoSim Labs, INC. Insider Trading Activity

VIVS Stock Data

4.90M
2.51M
Biotechnology
Biological Products, (no Diagnostic Substances)
Link
United States
SAN DIEGO